Boundless Bio director Kevin Tang buys $51,619 in BOLD shares

Boundless Bio, Inc. (BOLD) Director Kevin Tang recently acquired common stock totaling $51,619 through a series of transactions. The purchases occurred between October 22 and October 26, 2026, with prices ranging from $2.38 to $2.40 per share. The timing of these purchases is notable given the stock’s strong momentum, with shares up over 100% year-to-date and trading at $2.41. According to InvestingPro analysis, the stock appears undervalued at current levels, with a Fair Value of $2.53.

According to a recent filing, Mr. Tang, who is also a 10% owner of the company, acquired a total of 21,640 shares of Boundless Bio common stock. On October 22, 2026, Mr. Tang purchased 5,800 shares. This was followed by an acquisition of 6,234 shares on October 23, 2026. The final transaction reported was for 9,606 shares on October 26, 2026.

Following these transactions, Mr. Tang indirectly beneficially owns 3,011,749 shares of Boundless Bio. These shares are held through several entities including Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc., and Tang Capital Partners IV, Inc. Mr. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of Tang Capital Partners, LP and Tang Capital Partners International, LP. He is also the sole director and Chief Executive Officer of Tang Capital Partners III, Inc. and Tang Capital Partners IV, Inc., which are indirectly wholly owned by Tang Capital Partners, LP. Mr. Tang has a pecuniary interest in the shares beneficially held by these entities.